Imexpharm Corp
VN:IMP
Relative Value
The Relative Value of one IMP stock under the Base Case scenario is 45 432.68 VND. Compared to the current market price of 54 200 VND, Imexpharm Corp is Overvalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
IMP Competitors Multiples
Imexpharm Corp Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| VN |
I
|
Imexpharm Corp
VN:IMP
|
8.3T VND | 3.4 | 27.4 | 14.4 | 17.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
951.3B USD | 14.6 | 46.1 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
595.7B USD | 6.3 | 22.2 | 15.4 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282B CHF | 4.6 | 29.9 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
244.9B CHF | 5.6 | 22.4 | 13.8 | 17.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.2B GBP | 5.3 | 30.4 | 16.8 | 23.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.5B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.5B USD | 2.6 | 17.6 | 7.4 | 9.1 |